Eli Lilly and Company (LLY)vsScynexis Inc (SCYX)
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
SCYX
Scynexis Inc
$0.93
-0.46%
HEALTHCARE · Cap: $78.31M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 316288% more annual revenue ($65.18B vs $20.60M). LLY leads profitability with a 31.7% profit margin vs -41.8%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SCYX
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+30.0%
Fair Value
$1.11
Current Price
$0.93
$0.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Strong operational efficiency at 56.4%
Revenue surging 1809.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -16.5% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : SCYX
The strongest argument for SCYX centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 1809.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SCYX
The primary concerns for SCYX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while SCYX is a hypergrowth play — different risk/reward profiles.
SCYX carries more volatility with a beta of 1.15 — expect wider price swings.
SCYX is growing revenue faster at 1809.0% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 46/100), backed by strong 31.7% margins and 42.6% revenue growth. SCYX offers better value entry with a 30.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Scynexis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?